Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:46:06.937Z.
Consensus retrieved: 2026-10-06T10:02:38.018Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:46:06.937Z.
Quote observation: 2026-10-06T15:45:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e126544d6b89d716845e46a575ce394628d8118dbd26b88e4cb46db2a476fd9c
Forward PE Ratio (N/A) = Dated Quote Price ($1.42) / Consensus Forward EPS ($-0.38)
FORWARD PE RATIO
N/A
Codexis, Inc.
Market Cap
$152.20M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Codexis, Inc. (CDXS) | $152.20M | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $151.99M | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $150.96M | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $154.46M | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $155.42M | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $148.36M | N/A |
| LifeMD, Inc. (LFMDP)vs › | $147.97M | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.58M | N/A |
| Minerva Neurosciences, Inc. (NERV)vs › | $157.94M | N/A |
| Immuneering Corporation (IMRX)vs › | $145.88M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.42, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.38 | $-0.43 – $-0.34 | 4 | n/m |
| 2027-12-31 | $-0.28 | $-0.35 – $-0.13 | 3 | n/m |
| 2028-12-31 | $-0.11 | $-0.24 – $0.12 | 3 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
